UroGen Pharma Ltd.
URGNNasdaq
$40.23
↑ +0.6%Jul 17 close · end-of-day
Price
1Y↑ +180.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$140.5M
Net Income (TTM)
-$133.2M
Free Cash Flow (TTM)
-$166.0M
Gross Margin
89.8%
Operating Margin
-77.0%
Net Margin
-94.8%
ROE
107.2%
ROIC
—
Debt / Equity
-1.5
Net Cash
-$39.8M
Return 1Y
+161.1%
Company profile
UroGen Pharma Ltd. engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs. The company's lead product candidate is UGN-102, which is in Phase III clinical trials.
- CEO
- Elizabeth Barrett
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 200
- Website
- urogen.com
Earnings
URGN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$51.0M↑ +151.6%
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $11.8M | $48.0M | $64.4M | $82.7M | $90.4M | $109.8M |
| Gross profit | $10.8M | $42.9M | $56.7M | $73.4M | $81.5M | $97.3M |
| Operating income | -$126.7M | -$92.3M | -$79.0M | -$65.5M | -$96.8M | -$124.9M |
| Net income | -$128.5M | -$110.8M | -$109.8M | -$102.2M | -$126.9M | -$153.5M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | -$105.9M | -$84.9M | -$87.6M | -$76.4M | -$96.8M | -$162.4M |
| Free cash flow | -$107.1M | -$85.6M | -$87.8M | -$76.6M | -$97.1M | -$162.7M |
| Gross margin | 91.4% | 89.3% | 88.1% | 88.7% | 90.2% | 88.7% |
| Operating margin | -1074.2% | -192.1% | -122.8% | -79.2% | -107.1% | -113.7% |
| Net margin | -1088.9% | -230.7% | -170.6% | -123.6% | -140.4% | -139.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21.8M | $25.2M | $24.6M | $20.3M | $24.2M | $27.5M | $37.8M | $51.0M |
| Gross profit | $19.6M | $22.8M | $22.1M | $17.9M | $20.7M | $24.2M | $34.5M | $46.8M |
| Operating income | -$25.8M | -$17.5M | -$27.7M | -$36.9M | -$41.4M | -$27.4M | -$19.1M | -$20.3M |
| Net income | -$33.4M | -$23.7M | -$37.5M | -$43.8M | -$49.9M | -$33.3M | -$26.4M | -$23.6M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$23.7M | -$27.7M | -$13.6M | -$42.0M | -$39.8M | -$42.3M | -$38.3M | -$45.3M |
| Free cash flow | -$23.8M | -$27.8M | -$13.7M | -$42.1M | -$40.0M | -$42.4M | -$38.3M | -$45.4M |
| Gross margin | 89.8% | 90.3% | 89.9% | 88.5% | 85.3% | 88.1% | 91.3% | 91.9% |
| Operating margin | -118.3% | -69.6% | -112.6% | -182.3% | -171.2% | -99.7% | -50.5% | -39.8% |
| Net margin | -152.9% | -93.9% | -152.7% | -216.5% | -206.2% | -121.3% | -69.7% | -46.3% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.